TRANSLATIONAL RESEARCH IN ICH: FROM PATIENT TO GOOGLE TO CLINICAL TRIALS

MAGDY SELIM, M.D., PH.D.
PROFESSOR OF NEUROLOGY
BETH ISRAEL DEACONESS MEDICAL CENTER
DIVISION OF CEREBROVASCULAR DISEASES
HARVARD MEDICAL SCHOOL

RESEARCH ABSTRACT

A large body of pre-clinical data shows that hemoglobin degradation products, in particular iron, play an important role in secondary injury following intracerebral hemorrhage (ICH); and that the iron chelator, deferoxamine mesylate, has diverse neuroprotective effects in animal models of ICH. We undertook several preliminary studies to translate these pre-clinical data into the clinical setting, culminating in an ongoing NIH/NINDS-funded, multicenter, phase II trial (The iDEF Trial;Clinical Trials.gov ID: NCT02175225) to determine if it is futile to move deferoxamine forward into phase III evaluation as a therapeutic intervention for ICH. This talk will highlight the road to iDEF and the translational challenges along the way.

REFERENCES